Literature DB >> 15238775

Declining trend in transmission of drug-resistant HIV-1 in Amsterdam.

Daniela Bezemer1, Suzanne Jurriaans, Maria Prins, Lia van der Hoek, Jan M Prins, Frank de Wolf, Ben Berkhout, Roel Coutinho, Nicole K T Back.   

Abstract

OBJECTIVE: Symptomatic primary HIV infections are over-represented in the mainly hospital-based studies on transmission of resistant HIV-1. We examined a more general population for the prevalence of resistant HIV-1 strains among primary infections.
DESIGN: From 1994 to 2002 primary infections were identified within the Amsterdam Cohort Studies (ACS) among homosexual men and drug users, and at the Academic Medical Center (AMC). Whereas primary HIV-1-infected AMC patients, often presented with symptoms of acute retroviral syndrome, ACS participants largely seroconverted during follow-up and thus brought also asymptomatic primary infections to our study.
METHODS: Reverse transcriptase (RT) and protease sequences were obtained by population-based nucleotide sequence analysis of the first HIV RNA-positive sample available. Subtypes were identified by phylogenetic analysis. Mutations were identified based on the IAS-USA resistance table.
RESULTS: A total of 100 primary HIV-1 infections were identified (32 AMC and 68 ACS). Transmission of drug-resistant strains decreased over calendar time, with 20% [95% confidence interval (CI), 10-34%] of infections bearing drug-resistant mutations before 1998 versus only 6% (95% CI, 1-17%) after 1998. No multi-drug resistance pattern was observed. The median plasma HIV-1 RNA level of the first RNA positive sample was significantly lower for the individuals infected with a resistant strain versus those infected with wild-type, suggesting a fitness-cost to resistance. Four of seven non-B subtypes corresponded with the prevalent subtype in the presumed country of infection, and none showed resistance mutations.
CONCLUSIONS: The transmission of drug-resistant HIV-1 strains in Amsterdam has decreased over time. Monitoring should be continued as this trend might change.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15238775     DOI: 10.1097/01.aids.0000131357.52457.33

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  14 in total

Review 1.  Burden of nonnucleoside reverse transcriptase inhibitor resistance in HIV-1-infected patients: a systematic review and meta-analysis.

Authors:  Sonya J Snedecor; Lavanya Sudharshan; Katherine Nedrow; Abhijeet Bhanegaonkar; Kit N Simpson; Seema Haider; Richard Chambers; Charles Craig; Jennifer Stephens
Journal:  AIDS Res Hum Retroviruses       Date:  2014-07-08       Impact factor: 2.205

2.  Increased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-Acid insert in the reverse transcriptase.

Authors:  Lia van der Hoek; Nicole Back; Maarten F Jebbink; Anthony de Ronde; Margreet Bakker; Suzanne Jurriaans; Peter Reiss; Neil Parkin; Ben Berkhout
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

3.  Estimating the potential to prevent locally acquired HIV infections in a UNAIDS Fast-Track City, Amsterdam.

Authors:  Alexandra Blenkinsop; Mélodie Monod; Ard van Sighem; Nikos Pantazis; Daniela Bezemer; Eline Op de Coul; Thijs van de Laar; Christophe Fraser; Maria Prins; Peter Reiss; Godelieve J de Bree; Oliver Ratmann
Journal:  Elife       Date:  2022-08-03       Impact factor: 8.713

4.  Prevalence of transmitted drug resistance and impact of transmitted resistance on treatment success in the German HIV-1 Seroconverter Cohort.

Authors:  Barbara Bartmeyer; Claudia Kuecherer; Claudia Houareau; Johanna Werning; Kathrin Keeren; Sybille Somogyi; Christian Kollan; Heiko Jessen; Stephan Dupke; Osamah Hamouda
Journal:  PLoS One       Date:  2010-10-07       Impact factor: 3.240

5.  Etravirine (TMC-125): The evidence for its place in the treatment of HIV-1 infection.

Authors:  Hans-Jürgen Stellbrink
Journal:  Core Evid       Date:  2010-06-15

6.  Aggressive HIV-1?

Authors:  Ben Berkhout; Anthony de Ronde; Lia van der Hoek
Journal:  Retrovirology       Date:  2005-02-28       Impact factor: 4.602

7.  First line treatment response in patients with transmitted HIV drug resistance and well defined time point of HIV infection: updated results from the German HIV-1 seroconverter study.

Authors:  Fabia Zu Knyphausen; Ramona Scheufele; Claudia Kücherer; Klaus Jansen; Sybille Somogyi; Stephan Dupke; Heiko Jessen; Dirk Schürmann; Osamah Hamouda; Karolin Meixenberger; Barbara Bartmeyer
Journal:  PLoS One       Date:  2014-05-01       Impact factor: 3.240

8.  HIV drug-resistant strains as epidemiologic sentinels.

Authors:  María S Sánchez; Robert M Grant; Travis C Porco; Wayne M Getz
Journal:  Emerg Infect Dis       Date:  2006-02       Impact factor: 6.883

Review 9.  HIV-1 drug-resistance and drug-dependence.

Authors:  Chris Baldwin; Ben Berkhout
Journal:  Retrovirology       Date:  2007-10-25       Impact factor: 4.602

10.  Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands.

Authors:  Gijs A A Hubben; Jasper M Bos; Christa A Veltman-Starkenburg; Simon Stegmeijer; Henrik W Finnern; Bregt S Kappelhoff; Kit N Simpson; Andrea Tramarin; Maarten J Postma
Journal:  Cost Eff Resour Alloc       Date:  2007-11-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.